News We’re Watching: Cancer Screening Partnership, New Abbott Electrophysiology Head, V-Champs AI Challenge
Executive Summary
This week, Bioventus announced plans to sell its wound business; Pfizer and Thermo Fisher Scientific partnered to increase cancer screening access; and the FDA expanded the magnetic resonance imaging labeling for Abbott’s Eterna spinal cord stimulator.
You may also be interested in...
White House Takes Steps To Advance ‘Responsible’ AI That ‘Upholds Democratic Values’
The White House Office of Science and Technology Policy has released an updated national strategic framework outlining priorities and goals for federal investment in AI. Industry executive Peter Shen weighs in on the plan.
Minute Insight: FDA Approves Abbott’s SCS For Non-Surgical Back Pain
The approval, supported by the results of the randomized DISTINCT trial, includes all of Abbott’s spinal cord stimulation devices that deliver the proprietary BurstDR waveform.
Medtronic Earns CE Mark For Affera Ablation System, Touts New PFA Results
Results of the PULSED AF trial confirm that Medtronic’s PulseSelect pulsed field ablation is safe and effective for atrial fibrillation ablation. The company will likely incorporate PulseSelect into its Affera cardiac mapping and ablation system, which will soon be available in Europe.